Accession Number:



Drosophila as a Screening Platform for Novel Lung Cancer Therapeutics

Personal Author(s):

Corporate Author:

Icahn School of Medicine at Mount Sinai New York United States

Report Date:



The research in this grant is designed to explore the effects of genetic and genomic complexity in lung cancer progression and response to therapeutics. Using Drosophila, we are establishing a set of personalized fly lines, each which represents a separate patient. In this Progress Report, I discuss our initial studies in building these lines. In addition, I discuss our results with screening a library of 1200 FDA approved drugs. We provide evidence that a two drug cocktail, trametinib plus fluvastatin, synergize to improve efficacy and minimize toxicity in fly and human cell line models.

Descriptive Note:

Technical Report,01 Sep 2015,31 Aug 2016



Distribution Statement:

Approved For Public Release;

File Size: